Abstract
Alzheimer’s disease (AD) is a well-described neurological disorder characterized by the presence of a number of biological processes. Deposition of β-amyloid plaques in brain, one of the main features of AD pathology, was successfully modeled in the middle of the 1990s by a generation of the β-amyloid precursor protein (APP) transgenic mouse lines. The Thy1-APP751SL transgenic line, one of this “new generation” AD animal models, reproduces several characteristic features of Alzheimer`s disease such as Aβ peptide deposition, dystrophic neurite formation, and progressive neuronal death. A recently developed technique named difference gel electrophoresis (DIGE) made identification of qualitative and quantitative differences in protein expression between two biological samples considerably more sensitive, straightforward and reliable. Application of DIGE allows the study of the AD-related proteome to progress with a new level of confidence. Here, we describe application of a novel DIGE technique coupled with MS protein identification to the generation of a distinct AD-related protein expression profile using cortices of 14-month-old Thy1-APP751SL transgenic mice. Using this approach, we identified 15 different proteins which are significantly regulated in AD pathology. Resulting AD-related proteome comprises a number of proteins that were already known to be implicated in AD and neurodegeneration, as well as several proteins for which relationship with AD had not been shown before. Identified proteins were grouped according to their key biological pathways. Acquired data are discussed in the view of existing literature on the AD proteome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Afagh, A., Cummings, B. J., Cribbs, D. H., Cotman, C. W., & Tenner, A. J. (1996). Localization and cell association of C1q in Alzheimer’s disease brain. Experimental Neurology, 138, 22–32.
Baker, H., Grillo, M., & Margolis, F. L. (1989). Biochemical and immunocytochemical characterization of olfactory marker protein in the rodent central nervous system. The Journal of Comparative Neurology, 285, 246–261.
Bales, K. R., Dodart, J. C., DeMattos, R. B., Holtzman, D. M., & Paul, S. M. (2002). Apolipoprotein E, amyloid, and Alzheimer disease. Molecular Interventions, 2, 363–375.
Bales, K. R., Verina, T., Cummins, D. J., Du, Y., Dodel, R. C., Saura, J., et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer’s disease. Proceedings of the National Academy of Sciences of the United States of America, 96, 15233–15238.
Bigl, M., Bruckner, M. K., Arendt, T., Bigl, V., & Eschrich, K. (1999). Activities of key glycolytic enzymes in the brains of patients with Alzheimer’s disease. Journal of Neural Transmission, 106, 499–511.
Blanchard, V., Moussaoui, S., Czech, C., Touchet, N., Bonici, B., Planche, M., et al. (2003). Time sequence of maturation of dystrophic neurites associated with Abeta deposits in APP/PS1 transgenic mice. Experimental Neurology, 184, 247–263.
Boyett, K. W., DiCarlo, G., Jantzen, P. T., Jackson, J., O’Leary, C., Wilcock, D., et al. (2003). Increased fibrillar beta-amyloid in response to human clq injections into hippocampus and cortex of APP+PS1 transgenic mice. Neurochemical Research, 28, 83–93.
Buiakova, O. I., Baker, H., Scott, J. W., Farbman, A., Kream, R., Grillo, M., et al. (1996). Olfactory marker protein (OMP) gene deletion causes altered physiological activity of olfactory sensory neurons. Proceedings of the National Academy of Sciences of the United States of America, 93, 9858–9863.
Butterfield, D. A., & Lauderback, C. M. (2002). Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: Potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radical Biology & Medicine, 32, 1050–1060.
Buxbaum, J. N., & Tagoe, C. E. (2000). The genetics of the amyloidoses. Annual Review of Medicine, 51, 543–569.
Casserly, I., & Topol, E. (2004). Convergence of atherosclerosis and Alzheimer’s disease: Inflammation, cholesterol, and misfolded proteins. Lancet, 363, 1139–1146.
Castano, E. M., Roher, A. E., Esh, C. L., Kokjohn, T. A., & Beach, T. (2006). Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer’s disease and non-demented elderly subjects. Neurological Research, 28, 155–163.
Castegna, A., Aksenov, M., Aksenova, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., et al. (2002). Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radical Biology & Medicine, 33, 562–571.
Castegna, A., Aksenov, M., Thongboonkerd, V., Klein, J. B., Pierce, W. M., Booze, R., et al. (2002). Proteomic identification of oxidatively modified proteins in Alzheimer’s disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. Journal of Neurochemistry, 82, 1524–1532.
Chang, T. Y., Chang, C. C., Lin, S., Yu, C., Li, B. L., & Miyazaki, A. (2001). Roles of acyl-coenzyme A: Cholesterol acyltransferase-1 and -2. Current Opinion in Lipidology, 12, 289–296.
Charrier, E., Reibel, S., Rogemond, V., Aguera, M., Thomasset, N., & Honnorat, J. (2003). Collapsin response mediator proteins (CRMPs): Involvement in nervous system development and adult neurodegenerative disorders. Molecular Neurobiology, 28, 51–64.
Chen, J. W., Dodia, C., Feinstein, S. I., Jain, M. K., & Fisher, A. B. (2000). 1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities. The Journal of Biological Chemistry, 275, 28421–28427.
Condorelli, D. F., Nicoletti, V. G., Barresi, V., Conticello, S. G., Caruso, A., Tendi, E. A., et al. (1999). Structural features of rat GFAP gene and identification of a novel alternative transcript. Journal of Neuroscience Research, 56, 219–228.
Cottrell, B. A., Galvan, V., Banwait, S., Gorostiza, O., Lombardo, C. R., Williams, T., et al. (2005). A pilot proteomic study of amyloid precursor interactors in Alzheimer’s disease. Annals of Neurology, 58, 277–289.
Dickey, C. A., Loring, J. F., Montgomery, J., Gordon, M. N., Eastman, P. S., & Morgan, D. (2003). Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice. The Journal of Neuroscience, 23, 5219–5226.
Farrar, G., Altmann, P., Welch, S., Wychrij, O., Ghose, B., Lejeune, J., et al. (1990). Defective gallium-transferrin binding in Alzheimer disease and Down syndrome: Possible mechanism for accumulation of aluminium in brain. Lancet, 335, 747–750.
Fonseca, M. I., Zhou, J., Botto, M., & Tenner, A. J. (2004). Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer’s disease. The Journal of Neuroscience, 24, 6457–6465.
Frank, S., Gaume, B., Bergmann-Leitner, E. S., Leitner, W. W., Robert, E. G., Catez, F., et al. (2001). The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Developmental Cell, 1, 515–525.
Galasko, D. (2005). Biomarkers for Alzheimer’s disease – clinical needs and application. Journal of Alzheimer’s Disease, 8, 339–346.
Ginsberg, S. D., Hemby, S. E., Lee, V. M., Eberwine, J. H., & Trojanowski, J. Q. (2000). Expression profile of transcripts in Alzheimer’s disease tangle-bearing CA1 neurons. Annals of Neurology, 48, 77–87.
Glowinski, J., & Iversen, L. L. (1966). Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. Journal of Neurochemistry, 13, 655–669.
Gu, Y., Hamajima, N., & Ihara, Y. (2000). Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. Biochemistry, 39, 4267–4275.
Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K., & Hyman, B. T. (1997). APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. Journal of Neuropathology and Experimental Neurology, 56, 965–973.
Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., et al. (1997). Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. The Journal of Neuroscience, 17, 7053–7059.
Kanninen, K., Goldsteins, G., Auriola, S., Alafuzoff, I., & Koistinaho, J. (2004). Glycosylation changes in Alzheimer’s disease as revealed by a proteomic approach. Neuroscience Letters, 367, 235–240.
Koch, A., Thiemann, M., Grabenbauer, M., Yoon, Y., McNiven, M. A., & Schrader, M. (2003). Dynamin-like protein 1 is involved in peroxisomal fission. The Journal of Biological Chemistry, 278, 8597–8605.
Kumar-Singh, S., Pirici, D., McGowan, E., Serneels, S., Ceuterick, C., Hardy, J., et al. (2005). Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer’s disease are centered on vessel walls. The American Journal of Pathology, 167, 527–543.
Liao, L., Cheng, D., Wang, J., Duong, D. M., Losik, T. G., Gearing, M., et al. (2004). Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. The Journal of Biological Chemistry, 279, 37061–37068.
Lubec, G., Krapfenbauer, K., & Fountoulakis, M. (2003). Proteomics in brain research: Potentials and limitations. Progress in Neurobiology, 69, 193.
Lubec, G., Nonaka, M., Krapfenbauer, K., Gratzer, M., Cairns, N., & Fountoulakis, M. (1999). Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer’s disease brain is downregulated at the mRNA and dysregulated at the protein level. Journal of Neural Transmission. Supplementum, 57, 161–177.
Manevich, Y., Sweitzer, T., Pak, J. H., Feinstein, S. I., Muzykantov, V., & Fisher, A. B. (2002). 1-Cys peroxiredoxin overexpression protects cells against phospholipid peroxidation-mediated membrane damage. Proceedings of the National Academy of Sciences of the United States of America, 99, 11599–11604.
Marouga, R., David, S., & Hawkins, E. (2005). The development of the DIGE system: 2D fluorescence difference gel analysis technology. Analytical and Bioanalytical Chemistry, 382, 669–678.
Matsuoka, Y., Picciano, M., Malester, B., LaFrancois, J., Zehr, C., Daeschner, J. M., et al. (2001). Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer’s disease. The American Journal of Pathology, 158, 1345–1354.
McDonald, W. H., & Yates, J. R. (2002). Shotgun proteomics and biomarker discovery. Disease Markers, 18, 99–105.
Messing, A., & Brenner, M. (2003). GFAP: Functional implications gleaned from studies of genetically engineered mice. Glia, 43, 87–90.
Namekata, K., Imagawa, M., Terashi, A., Ohta, S., Oyama, F., & Ihara, Y. (1997). Association of transferrin C2 allele with late-onset Alzheimer’s disease. Human Genetics, 101, 126–129.
Orange, P., Hawkins, E., Story, C., & Fowler, S. (2000). Fluorescence 2-D difference gel electrophoresis. Life Science News, 5, 1–4.
Piot-Grosjean, O., Cudennec, C. L., Dhenain, M., Delay-Goyet, P., & Delatour, B. (2004). 9th international conference on Alzheimer’s disease and related disorders. Philadelphia, USA, personal communication.
Poduslo, J. F., Curran, G. L., Wengenack, T. M., Malester, B., Duff, K. (2001) Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer’s disease. Neurobiology of Disease, 8, 555–567.
Price, D. L., & Sisodia, S. S. (1994). Cellular and molecular biology of Alzheimer’s disease and animal models. Annual Review of Medicine, 45, 435–446.
Puglielli, L., Konopka, G., Pack-Chung, E., Ingano, L. A., Berezovska, O., Hyman, B. T., et al. (2001). Acyl-coenzyme A: Cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nature Cell Biology, 3, 905–912.
Ross, G. W., O’Callaghan, J. P., Sharp, D. S., Petrovitch, H., Miller, D. B., Abbott, R. D., et al. (2003). Quantification of regional glial fibrillary acidic protein levels in Alzheimer’s disease. Acta Neurologica Scandinavica, 107, 318–323.
Schonberger, S. J., Edgar, P. F., Kydd, R., Faull, R. L., & Cooper, G. J. (2001). Proteomic analysis of the brain in Alzheimer’s disease: Molecular phenotype of a complex disease process. Proteomics, 1, 1519–1528.
Shen, Y., & Meri, S. (2003). Yin and Yang: Complement activation and regulation in Alzheimer’s disease. Progress in Neurobiology, 70, 463–472.
Shin, S. J., Lee, S. E., Boo, J. H., Kim, M., Yoon, Y. D., Kim, S. I., et al. (2004). Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics, 4, 3359–3368.
Sizova, D., Charbaut, E., Delalande, F., Poirier, F., High, A., Parker, F., et al. (2007). Proteomic analysis of brain tissue from an Alzheimer’s disease mouse model by two-dimensional difference gel electrophoresis. Neurobiology of Aging, 28, 357–570.
Tabernero, A., Medina, A., Sanchez-Abarca, L. I., Lavado, E., & Medina, J. M. (1999). The effect of albumin on astrocyte energy metabolism is not brought about through the control of cytosolic Ca2+ concentrations but by free-fatty acid sequestration. Glia, 25, 1–9.
Teunissen, C. E., Vente, J., Steinbusch, H. W., & Bruijn, C. D. (2002). Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid. Neurobiology of Aging, 23, 485–508.
Todorich, B. M., & Connor, J. R. (2004). Redox metals in Alzheimer’s disease. Annals of the New York Academy of Sciences, 1012, 171–178.
Tsuji, T., Shiozaki, A., Kohno, R., Yoshizato, K., & Shimohama, S. (2002). Proteomic profiling and neurodegeneration in Alzheimer’s disease. Neurochemical Research, 27, 1245–1253.
Ujiie, M., Dickstein, D. L., Carlow, D. A., & Jefferies, W. A. (2003). Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation, 10, 463–470.
van Beek, J., Elward, K., Gasque, P. (2003). Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann. NY Acad. Sci. 992, 56–71.
Vercauteren, F. G., Clerens, S., Roy, L., Hamel, N., Arckens, L., Vandesande, F., et al. (2004). Early dysregulation of hippocampal proteins in transgenic rats with Alzheimer’s disease-linked mutations in amyloid precursor protein and presenilin 1. Molecular Brain Research, 132, 241–259.
Wang, X., Phelan, S. A., Forsman-Semb, K., Taylor, E. F., Petros, C., Brown, A., et al. (2003). Mice with targeted mutation of peroxiredoxin 6 develop normally but are susceptible to oxidative stress. The Journal of Biological Chemistry, 278, 25179–25190.
Webster, S., Glabe, C., & Rogers, J. (1995). Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochemical and Biophysical Research Communications, 217, 869–875.
Wisniewski, H. M., Vorbrodt, A. W., & Wegiel, J. (1997). Amyloid angiopathy and blood-brain barrier changes in Alzheimer’s disease. Annals of the New York Academy of Sciences, 826, 161–172.
Wolfe, M. S. (2002). Therapeutic strategies for Alzheimer’s disease. Nature Reviews. Drug Discovery, 1, 859–866.
Wolozin, B., Brown, J., Theisler, C., & Silberman, S. (2004). The cellular biochemistry of cholesterol and statins: Insights into the pathophysiology and therapy of Alzheimer’s disease. CNS Drug Reviews, 10, 127–146.
Yao, P. J., Zhu, M., Pyun, E. I., Brooks, A. I., Therianos, S., Meyers, V. E., et al. (2003). Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer’s disease. Neurobiology of Disease, 12, 97–109.
Yasojima, K., Schwab, C., McGeer, E. G., & McGeer, P. L. (1999). Up-regulated production and activation of the complement system in Alzheimer’s disease brain. The American Journal of Pathology, 154, 927–936.
Acknowledgments
I would like to thank Dr. Anita Diu-Hercend for indispensable participation in all steps of this work, for fruitful discussions, for continuous help and encouragement, and for critical reading of the present manuscript. I am very grateful to Dr. Elodie Charbaut for her help in data treatment, evaluation, and representation. The author also sincerely acknowledges Dr. Veronique Blanchard and Dr. Philippe Delay-Goyet (AD mouse model), Emmanuelle Deretz, Sophie Bouvier, Dr. Fabienne Parker and Dr. Marc Duchesne (proteomics), and Dr. Francois Delalande, Dr. Anthony High, Dr. Florence Poirier, and Dr. Alain Van Dorsselaer (mass spectroscopy) for their contribution to the generation of experimental data.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Sizova, D. (2011). Protein Expression Profile of Alzheimer’s Disease Mouse Model Generated by Difference Gel Electrophoresis (DIGE) Approach. In: Clelland, J. (eds) Genomics, Proteomics, and the Nervous System. Advances in Neurobiology, vol 2. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-7197-5_19
Download citation
DOI: https://doi.org/10.1007/978-1-4419-7197-5_19
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-7196-8
Online ISBN: 978-1-4419-7197-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)